

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
**WO 01/97850 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
00250194.8 23 June 2000 (23.06.2000) EP  
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**  
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

WO 01/97850 A2



**Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their  
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of  
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an  
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonnier et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1  
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during  
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce  
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also  
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and  
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *Cell* 87, 1171-1180). Conversely, increased vascularization was  
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or  
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological  
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor  
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the  
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents  
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).



Examples for delivery-/Targeting-Systems have been described as ligand/  
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,  
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell  
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-  
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),  
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example  
 molecules of general formula I

15



20

I,

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R<sub>3</sub> und R<sub>4</sub> a) each independently from each other have the meaning  
 of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

G

20

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or  
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted  
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,  
halogen, alkyl, substituted alkyl, hydroxy, etherificated or  
esterificated hydroxy, nitro, cyano, carboxy, esterificated  
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted  
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,  
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,  
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,  
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if  
15 more than one rest Z is present ( $m \geq 2$ ), the substituents Z are  
equal or different from each other, and wherein the bonds  
marked with an arrow are single or double bonds; or an N-  
oxide of said compound, wherein one or more N-atoms carry  
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive  
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,  
respectively, which results in a prevention of tumor growth and tumor spread, are  
for example

anthranilic acid derivatives of general formula IV

30



in which

A

has the meaning of group  $=NR^2$ ,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group

10




15

or A, Z and  $R^1$  together form the group

20

12



m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/or R<sub>a</sub> and/or R<sub>b</sub> together with R<sub>c</sub> and/or R<sub>d</sub> or R<sub>c</sub> together with R<sub>e</sub> and/or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

has the meaning of group =NR<sup>9</sup> or =N-,has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R<sup>2</sup>

has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,


R<sup>3</sup>

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>

independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or


C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group



- 5      R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>      independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts.


10      These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.


More preferentially compounds of general formula V




- 15      V,  
in which  
R<sup>1</sup>      has the meaning of group

20






in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,



in which  $R^7$  is  $-CH_3$  or chloro,




in which  $R^8$  is  $-CH_3$ , fluoro, chloro or  $-CF_3$

in which  $R^4$  is fluoro, chloro, bromo,  $-CF_3$ ,  $-N=C$ ,  $-CH_3$ ,  $-OCF_3$  or  $-CH_2OH$

in which  $R^6$  is  $-CH_3$  or chloro

$R^2$

has the meaning of pyridyl or the group



and

$R^3$

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions



a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

20

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

30

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites  
5 formation in patients. It is also possible to suppress VEGF oedemas.  
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,  
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.  
If necessary, the compositions additionally contain additives, such as  
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.  
These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients  
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with  
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in  
sequential order such that the biological response to interference with one  
ligand/receptor system overlaps with the biological response to interference with a  
second ligand/receptor system. Alternatively, combined functional interference  
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and  
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via  
Angiopoietin/Tie receptor systems can be performed simultaneously, or in  
sequential order such that the biological response to functional interference with a  
ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both  
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which  
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor  
systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,  
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2  
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).  
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and  
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor  
25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal  
purposes. Such diseases are, for example, cancer, cancer metastasis,  
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of  
30 the present invention can be applied orally, parenterally, or via gene therapeutic  
methods.

Therefor the present invention also concerns the use of pharmaceutical  
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections  
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

## 5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with  $1 \times 10^6$  transfected  
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,  
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the
- 15 tumors to a size of approx. 250 mm<sup>2</sup> to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.



**Example 2**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in  
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of  
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its  
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000  
20 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 3**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>3</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

**Example 4**

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

**Example 5**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-  
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.  
 15 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+



Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>3</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 6**

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-  
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of  
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a

10 reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

### Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the  
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of  
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-  
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

## CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I  
which modulate the biological function of one or several of the VEGF/VEGF  
5 receptor systems, and comprising one or several agents as compound II which  
modulate the biological function of one or several of the Angiopoietin/Tie  
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I  
10 which are targeted to the endothelium via one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
modulate the biological function of one or several of the Angiopoietin/Tie  
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I  
which modulates the biological function of one or several of the VEGF/VEGF  
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems  
and comprising one or several agents as compound II which are targeted to  
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I  
which modulate the biological function of one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
are targeted to the endothelium via one or several of the Angiopoietin/Tie  
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I  
which are targeted to the endothelium via one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie  
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound  
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,  
b) compounds which inhibit ligand binding to receptors,  
c) compounds which inhibit activation of intracellular signal pathways of the receptors,  
d) compounds which inhibit or activate expression of a ligand or of a  
25 receptor of the VEGF or Tie receptor system,  
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor  
30 systems,  
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.



11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- k) delivery systems, such as antibodies, ligands, high-affinity binding  
10 oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- l) delivery systems, such as antibodies, ligands, high-affinity binding  
15 oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as

25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as

30 compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R<sub>3</sub> und R<sub>4</sub>

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,  
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

5 G has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

$R_1$  and  $R_2$  independently from each other have the meaning of H or lower alkyl,

20 X has the meaning of imino, oxa or thia;

Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and


Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N- mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,

25 30 whereas, if more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,  
 wherein one or more N-atoms carry an oxygen atom,  
 or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group  $=NR^2$ ,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms  
 or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  
 $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the  
 group


15



or A, Z and  $R^1$  together form the group


20

44




5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R <sub>a</sub> , R <sub>b</sub> , R <sub>c</sub> , R <sub>d</sub> , R <sub>e</sub> , R <sub>f</sub>	independently from each other have the meaning of hydrogen, C <sub>1-4</sub> alkyl or the group =NR <sup>10</sup> , and/ or R <sub>a</sub> and/ or R <sub>b</sub> together with R <sub>c</sub> and or R <sub>d</sub> or R <sub>e</sub> together with R <sub>e</sub> and/ or R <sub>f</sub> form a bound, or up to two of the groups R <sub>a</sub> -R <sub>f</sub> form a bridge with each up to 3 C-atoms with R <sup>1</sup> or R <sup>2</sup> ,
10	X	has the meaning of group =NR <sup>9</sup> or =N-,
	Y	has the meaning of group -(CH <sub>2</sub> ) <sub>p</sub> ,
	p	has the meaning of integer 1-4,
15	R <sup>1</sup>	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C <sub>1-6</sub> -alkyl, or C <sub>1-6</sub> -alkyl or C <sub>1-6</sub> -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R <sup>2</sup>	has the meaning of hydrogen or C <sub>1-6</sub> -alkyl, or form a bridge with up to 3 ring atoms with R <sub>a</sub> -R <sub>f</sub> together with Z or R <sub>1</sub> ,
25	R <sup>3</sup>	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,  
 R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> independently from each other have the meaning  
 of hydrogen, halogene or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl  
 or C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or  
 optionally substituted with one or more of  
 halogene, or R<sup>5</sup> and R<sup>6</sup> together form the group



R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> independently from each other have the meaning  
 of hydrogen or C<sub>1-6</sub>-alkyl,  
 as well as their isomers and salts,


and/ or a compound of general formula V



V,


in which

R<sup>1</sup> has the meaning of group




in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,

5



in which  $R^7$  is  $-CH_3$  or chloro,



in which  $R^8$  is -CH<sub>3</sub>, fluoro, chloro or -CF<sub>3</sub>


in which  $R^4$  is fluoro, chloro, bromo, -CF<sub>3</sub>, -N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or -CH<sub>2</sub>OH

in which  $R^6$  is -CH<sub>3</sub> or chloro

5

$R^2$

has the meaning of pyridyl or the group



10

and

$R^3$

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium



hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

- 5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
- 10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
- 20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2



Fig. 3

BEST AVAILABLE COPY




Fig. 4

BEST AVAILABLE COPY




Fig. 5




Fig. 6

BEST AVAILABLE COPY

## Sequence Identifier

5

&lt;110&gt; Schering Aktiengesellschaft

10

&lt;120&gt; Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

&lt;130&gt; 51867AEPMLXX00-P

15

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 59

20

&lt;210&gt; 1

&lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

25

&lt;400&gt; 1

30

35

40

45

50

55

```
ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatgggt ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
ttggaatggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgtgaga 660
tggaccgctg agaagcgga cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccacaaacgca acctaacca agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc agggcgagca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtccacagg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcagggtggg ctgcatagac tcatttaatg ttaaacgcca tcaggggcct ctctcccggt 1320
ttctgccagg ggtttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcct tctggctctc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgaccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtccac attcgtacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggtctttc tgctggtgct 1620
cttggacggg cgggtagtct tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggaact gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct
```

60

&lt;210&gt; 2

&lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctaccag 60  
 acactaacia cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
 tcaacttact tctgtggcc cattagggaa gtggtgacct cgggagctat ttgctgttg 180  
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240  
 tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480  
 aagaaaatct tttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggcct 540  
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

&lt;400&gt; 3

tagagatggt ggttgatgac ccccggtatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120  
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctgcagctct tcagaaacag 180  
 ttgttaagct tctgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tctgtcgcct tgccaggtctg tgatcaggaca ctgtcagag ttacaccttt ggatgtggcc 360  
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420  
 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480  
 30 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 35 <213> Human

&lt;400&gt; 4

cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60  
 40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctgggtccg tgtaagggtc tgagaagggtg ccctgggtcg 180  
 ggggtgctgc ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240  
 gcaccaactc cagcagggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300  
 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcagggtg 360  
 45 ctgctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420  
 ggaagcctgc ctctagcaca ctcttgacga gcacactggc gacatagggtg cccatcagtg 480  
 ctccgcggtat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540  
 cggccgcccag cgcccgtctc acctgtgggt ccttggccgg cagtgcctgc agctccccct 600  
 ccttctgccc cagccgtctc tctcgccgag acaggtaaat gacatggccc aggttagacca 660  
 50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720  
 aggcctgggt atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactgcggc ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttacccaacca cggctgagtg ctctggacc tgggtccagca 900  
 acttctccac gaagccccag tcacccatgg ctcccgggccc tccgtcggca aggagacaga 960  
 55 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcaggggag 1020  
 gtctgccacg cccgttctac cgcctgctg cggggcgccc cagggtggagg tggggacgat 1080  
 ggcggagtg acgcccgcg

<210> 5  
 60 <211> 1015  
 <212> DNA  
 <213> Human

&lt;400&gt; 5

65 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgc	ttttgaaaa	gttgaggtg	aaatgatgg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttgggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaagt	gggcccaggc	240
5	ccagacccaa	gaggagagg	tggtcccgag	acacccccgg	atgtcagcat	ccccgcacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgtctg	ggaacagggt	acaggggcca	agcgcttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
	gtcccttcag	tcctctggtt	atgacctcaa	gtcctacttg	ggcctgcag	cccagcctgt	540
10	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttgctttatc	aactctaa	ctctttgtac	ggacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggcccgtga	720
	ctgggcaggc	ttctctgtag	aaccccagg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaactcttg	cattcacaga	ccacctccac	aattgttata	840
15	accaaaggcc	tctctgttctg	ttatttcact	taaatcaaca	tgtctattttg	tttttactca	900
	ctctgcactt	tagctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaaataat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
20	<211> 2313						
	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctggtggtg	agcagggacg	gtgcaccgga	cggcgggatc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcgggcggg	gggcagctct	cggggctgct	120
	ggtattacct	gcgcactctc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatgggtc	tatggcaacg	tgcacgtgag	cacagagtc	aacctgcagg	240
30	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggtccacg	gcctcccagt	300
	ccaactatgc	caaggagctc	agacttcacca	cccggcctca	ggaatgccatc	tgacagatgt	360
	ggctgaatgc	tcgccgcgac	ctggaccgca	tcaatgccag	cttcgcccgag	tgccagggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgccctgtctc	ttcatgctga	540
35	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaaagg	600
	ataaggaaag	cgtgctgctg	aacaaacgcg	tggcggaggga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtga	720
	agccctctgc	ctgccctctg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggaactccat	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
40	ctcggaattg	gcctccatcc	gcagagcctg	cgaccacatg	ccagcctca	tgagctccaa	900
	ggtggaggag	ctggcccggga	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaaagcca	gcagggcctg	cgggccagtc	aggaggcgaa	1020
	acagaagggt	gagaaggagg	ctcaggcccc	ggaggccaag	ctccaagctg	aatgtctccg	1080
	gcagaccctg	ctagcgtctg	aggagaagcg	ggtgctcggg	aaaggaacag	acaacctggc	1140
45	caaggagctg	gaagagaaga	agagggaagg	ggagcagctc	aggatggagc	tggccatcac	1200
	aaactcagcc	ctggacacct	gcataagac	caagtgcag	ccgatgatgc	cagtgtcaag	1260
	gcccatgggc	cctgtcccca	acccccagcc	catcgaccac	gctagcctgg	aggagttaa	1320
	gaggaagatc	ctggagctcc	agaggcccc	tgcaggcatc	cctgtagccc	catccagttg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gattggccga	ctcggcggtt	tgcggaagt	1440
50	gcagggatat	gctcacagcg	cccgacacaa	ccccctcccg	ccgcccccaa	ccaccagggg	1500
	ccaccatcac	acaactccct	gcatacaaac	ccctagtacc	ctctcacacc	cgcacccgcg	1560
	cctcacgcat	cctcacccag	agcacacggc	cgcggagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcacctg	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
55	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
	tcacacagag	gcggcgatgg	catcacacag	acggtgatga	tgtcacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatattggac	caacatcaca	tgacagcatg	1920
	ccctttcaca	cacactttct	accataattct	cacctagtgt	acagttcccc	cgacctggcg	1980
	acacgggcca	aggtaccacc	aggatcccat	ccccctccgc	acagcccttg	gccccagcac	2040



<212> DNA  
<213> Human

<400> 7

5

10

```
gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccttgag ctattaataa tctatgtggc tagtgcgat atatttgtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc
```

<210> 8

15

<211> 157  
<212> DNA  
<213> Human

<400> 8

20

```
tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgtga aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg
```

25

<210> 9  
<211> 561  
<212> DNA  
<213> Human

30

<400> 9

35

40

```
aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatattt ttgctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgata 480
ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a
```

<210> 10

45

<211> 1508  
<212> DNA  
<213> Human

<400> 10

50

55

60

65

```
cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactc 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaacgtgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt ccctcttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgcccgtg taaaaactca 660
aacacagttt gctgcaaaagt tcccactgtc ccccctagga actttgaaaa accaactatg 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840
ctgtgttgcg gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaatt ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaact 1020
```

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatatttt 1080  
 gtatatataca taatatattgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140  
 cacaaaatat tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtatgttt 1200  
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260  
 10 ttcattgtata ttgtacagtt acagtataat tcaaccttta ttttctaatt ttttcaacat 1320  
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataattta 1380  
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440  
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
 aaaaaaaa  
 <210> 11  
 <211> 389  
 <212> DNA  
 <213> Human  
 15 <400> 11  
 20 gggcaggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60  
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtagagaca agtgccccgac 120  
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
 ctgtcctgct ggaaacccaa gggcagatc ttactgcatg agagctctgg acatttctta 240  
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300  
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360  
 25 acctcggcgc cgaccacgct ggttaccga  
 <210> 12  
 <211> 981  
 <212> DNA  
 <213> Human  
 30 <400> 12  
 35 tttttttttt ttggattgca aaaatttatt aaaattggag aactgtttt aatcttcttg 60  
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120  
 ccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggcatataaa aaccctagtt 240  
 taggataaca acatatattt caggggcaaaa tacaattgtg tgatgcttgt tagtagagta 300  
 acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360  
 40 cattacatca ttggttacac tgaatcatc cacatgtacc aaaagctgac tcacctagtt 420  
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccatttaaa atttgccta 480  
 ctcaatttcc ttctcagta cattttaact tttaaacagc taatcactcc catctacaga 540  
 ttaagggtga tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaaa 600  
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660  
 45 cacacagtgat agtcaagcgc actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780  
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
 agtagctatt ctcatccttc cttggggaca caactgtcca taagggtgcta tccagagcca 900  
 cactgcatct gcacccagca ccatacctca caggagtcca ctccacagag ccgcctgtat 960  
 50 ataagagttc tttttagtgac g  
 <210> 13  
 <211> 401  
 <212> DNA  
 <213> Human  
 55 <400> 13  
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120  
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180  
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
 gtggtcatca cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300  
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360  
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t  
 <210> 14

<211> 1002  
 <212> DNA  
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60  
 acagttgttg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120  
 10 tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180  
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240  
 gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgatatc 300  
 taaaagtcac ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360  
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420  
 15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480  
 tactgaaaaa aatgggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540  
 tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600  
 attaatagac ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660  
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720  
 attcaataaa cattagccaa gctaattgtcc caagccactg tgccaggat taacaatata 780  
 20 acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840  
 attcattaaa atttttgggtg catcagaatc atgaggagct tgtcaaaaat gtaaatctct 900  
 gcctatgttc tcagatattc tggtaggtc aggagtggga acccaaatc aattctttta 960  
 acaaacacta aagggtgattc taacacaggc ggtgtgagga cc

25 <210> 15  
 <211> 280  
 <212> DNA  
 <213> Human

30 <400> 15

cgagggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tatectattt 60  
 ataataattc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120  
 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180  
 35 aactgtatta tgactctcaa tttttaaaca ttttaaaaaa tgttagtgtt tgttaagcac 240  
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16  
 <211> 2041  
 <212> DNA  
 <213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60  
 atagaggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120  
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttga 180  
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240  
 aattttgtta ttgccttctt tagagacttt ataatctcta gttgattttc aaggacttga 300  
 50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360  
 ttacctctag catcaattct tttataaaga atgctaataa aattacattt tttgttcagt 420  
 aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480  
 caggtagata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540  
 gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600  
 55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660  
 tagatatattg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720  
 gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780  
 accccctcca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840  
 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900  
 60 ttctctgtaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960  
 tgggtctcca tttatccaga gtccactgggt tgggttatta ccacttaaac cattagtact 1020  
 atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080  
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140  
 ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200  
 65 gtaaatgact ctgggaggat gctaagcga gagcctcaga ctggtgttac atctgatag 1260  
 aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtccc	tgaaggcttt	aatttttttag	caaggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattccttcta	actggcaact	1500
5	ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggatttcag	gttctcccg	gatttgcata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaa	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttcacc	1740
	tccccggtttc	tgaggatcat	ctttattaac	agaatcttg	ttagattcgt	tagggacaga	1800
10	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaag	1860
	tgagtccacag	atgaaggcag	ctgttggttg	attataaaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcat	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagtctc	120
25	agatactcag	gagactgagc	tggaaggat	cacttgagcc	caagaagttc	aaggttacag	180
	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
35	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttggtga	tcacattgtg	caaaatggtg	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttggtgg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtcctttgg	gttgcttttt	attaatgagg	agactattgt	300
40	gatggcatat	ctcttcacta	tatttaatgc	tttcagggga	gtgttcattt	tcatctttca	360
	ctgtgctctc	caaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctcg	tattctctcg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtagacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttggtgact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtcggag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggagga	1260
55	gtgagaatga	ggacatttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatgtgta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggcca	catgagagta	ttaataaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tggtgtaaaa	aagatgactg	aaccttgacg	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattatttgt	tacaaagaaa	agagatgcca	1680
	gccagggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaat	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgcagttc	actgcaaatc	ttttacatta	aggcaaat	tgaataacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatattg	ttctattgct	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgatcattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	gggtgcacat	ggtatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattacttac	atttaaatat	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcacccct	gtttattctt	gaacagaggg	caaaaggggc	actgggcact	tctcacaac	2460
	tttctagtga	acaaaagggt	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
10	actcttccat	attccttctg	cctatatatta	gtaatttaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gccccatcact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210>	19					
	<211>	276					
	<212>	DNA					
	<213>	Human					
20	<400>	19					
	ctccctaaat	gattttaaaa	taaattggat	aaacatatga	tataaagtgg	gtactttaga	60
	aaccgccttt	gcataatttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaac	aaaaccagga	cctcccaact	gcatgcctca	agtcctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210>	20					
	<211>	2361					
30	<212>	DNA					
	<213>	Human					
	<400>	20					
35	attgtaccag	ccttgatgaa	cgtgggccct	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	ttgtcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggtg	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaagag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtattggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagtgtga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
45	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tgagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccatacc	ctgtatctgg	cggagaacca	tgacatcat	gagtgtgacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggaagc	840
	tgctttttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
50	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgag	cgatagggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgga	gagctgaaa	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
55	gtggtcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	cctttacctt	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtag	cggcagggtc	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	accctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
60	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcag	gactacctgg	1560
	tcacaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccgtg	atccgccagg	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtccact	1740
	tcctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcggaa	agtgatgctg	1800
65	atgcgcccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gcccggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

5	ctgtgattgc	tgactacttt	ggcagagggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
	gtccactctt	catctaattg	cacagccctc	acaagactaa	agcggaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctctttaac	taggcaggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
10	ttggaaaaaa	aagctggttt	c				
	<210>	21					
	<211>	179					
	<212>	DNA					
15	<213>	Human					
	<400>	21					
	agggtgtaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
20	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210>	22					
	<211>	905					
	<212>	DNA					
25	<213>	Human					
	<400>	22					
30	tttttttttt	ttctttaacc	gtgtgggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaatgttcc	agtttagaagg	aattcaaacy	gaatgccaa	gtccaagcca	ggctcaagaa	120
	ataaaaagg	aggtttgag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtgggtggaa	300
	taggggtcatt	aataactatg	aatatatctt	ttagaagggtg	accatttttg	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaag	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcatgcca	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtga	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaaggc	taccaggagc	ctaattgcctc	tttcaaaccat	tgggggaacc	agtagaaaaa	660
	ggcagggtctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
	cctgaagatg	gtaaccacagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaaagaagg	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
40	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccaggaat	900
	gttga						
	<210>	23					
	<211>	2134					
	<212>	DNA					
	<213>	Human					
50	<400>	23					
	ggtctcttct	ttcctttttt	tttttccaaa	agtgttcttt	tattttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
55	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctt	cagcagcctc	360
	ccaccacaaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggaccctgt	tctacacacc	420
	tcatTTTTgt	tccggcgttt	catactcctt	gtgtgattgt	actgattttc	atgagacaca	480
	agttacttct	ttactccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggaggtagt	aagctcattg	tgtctcctct	agcttttacc	agcatctaatt	gcttccactgc	600
60	tttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagtgtg	tttttctctca	660
	aatgaattca	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccattttgc	720
	gttatttcac	gttgctgagc	ctttctctca	tgttgaaaca	tctgaagttt	taattctcgg	780
	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaag	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	cagggtcttag	900

	taaaatctca	cttttctcct	acttttcatt	tcccaacccc	catgatacta	agtatttgat	960
	aagtaccagg	aaacaggggt	tgtaatatgt	ctaacttttt	ttgacaattg	ctttgttttt	1020
	tctaaacttg	taatatagtg	aacaaaagaa	ataataataa	taatgcccg	ggctttatta	1080
5	tgctatatca	ctgctcagag	gttaataatc	ctcactaact	atcctatcaa	atgtgcaact	1140
	ggcagtttac	tctgatgatt	caactccttt	tctatctacc	cccataatcc	caccttactg	1200
	atacacctca	ctggttactg	gcaagatacg	ctggatccct	ccagccttct	tgctttccct	1260
	gcaccagccc	ttcctcactt	tgccctgccc	tcaaagctaa	caccacttaa	accacttaac	1320
	tgcaattctg	cattgtgcaa	aagtctatga	aatgtttagg	tttctttaaa	ggatcacagc	1380
10	tctcatgaga	taacacccct	ccatcatggg	acagacactt	caagcttctt	tttttgtaac	1440
	ctttcccaca	ggctcttagaa	catgatgacc	actccccag	ctgccactgg	gggcagggat	1500
	ggctctgcaca	aggctctggg	ctggctggct	tcacttcctt	tgcacactcg	gaagcaggct	1560
	gtocattaat	gtctcggeat	tctaccagtc	ttctctgcca	acccaattca	catgacttag	1620
	aacattcgcc	ccactcttca	atgacccatg	ctgaaaaagt	ggggatagca	ttgaaaagatt	1680
15	caactcttctt	ctttacgaag	taggtgtatt	taattttagg	tcgaagggca	ttgccacag	1740
	taagaacctg	gattgtcaag	ggctctttga	gagggtctaaa	gctgcgaatt	ctttccaatg	1800
	ccgcagagga	gccgctgtac	ctcaagacaa	cacctttgta	cataatgtct	tgctctaagg	1860
	tggaacaaagt	gtagtccacca	ttaagaatat	atgtgccatc	agcagctttg	atggcaagaa	1920
	agctgccatt	gttctctggat	cccctctggt	tccgctgttt	cacttcgatg	ttggtggctc	1980
20	cagttggaat	tgtgatgata	tcatgatata	caggttttgc	actagtaact	gatcctgata	2040
	tttttttaca	agtagatcca	tttccccgc	aaacaccaca	tttatcaaac	ttctttttgg	2100
	agtctatgat	gcgatcacia	ccagctttta	caca			
	<210>	24					
	<211>	1626					
25	<212>	DNA					
	<213>	Human					
	<400>	24					
30	ggacaatttc	tagaatctat	agtagtatca	ggatatat	tgctttaaaa	tatatatttg	60
	ttattttgaa	tacagacatt	ggctccaaat	tttcatcttt	gcacaatagt	atgacttttc	120
	actagaactt	ctcaacattt	gggaactttg	caaatatgag	catcatatgt	gttaaggctg	180
	tatcatttta	tgctatgaga	tacattgttt	tctccctatg	ccaaacaggt	gaacaaacgt	240
	agttgttttt	tactgatact	aaatgtttgc	tacctgtgat	tttatagtat	gcacatgtca	300
35	gaaaaaggca	agacaaatgg	cctcttgtac	tgaatacttc	ggcaaaactta	ttgggtcttc	360
	attttctgac	agacaggatt	tgactcaata	ttttagagac	ttgcgtagaa	tggtattacat	420
	ggtagtgatg	cactggtaga	aatgggtttt	agttattgac	tcagaattca	tctcaggatg	480
	aatcttttat	gtctttttat	tgtaagcata	tctgaattta	ctttataaag	atgggttttag	540
	aaagctttgt	ctaaaaattt	ggcctaggaa	tggttaacttc	attttcagtt	gccaaggggg	600
40	agaaaaataa	tatgtgtgtt	gttatgttta	tgtaacata	ttattaggtta	ctatctatga	660
	atgtatttaa	atatttttca	tattctgtga	caagcattta	taatttgcaa	caagtggagt	720
	ccatttagcc	cagtgggaaa	gtcttggaac	tcagggttacc	cttgaaggat	atgctggcag	780
	ccatctcttt	gatctgtgct	ttaaactgtaa	tttatagacc	agctaaatcc	ctaacttggg	840
	tctggaatgc	attagttatg	ccttgtacca	ttcccagaat	ttcaggggca	tcgtgggttt	900
45	ggcttagtga	ttgaaaacac	aagaacagag	agatccagct	gaaaaagagt	gatcctcaat	960
	atcctaacta	actggctctc	aactcaagca	gagtttcttc	actctggcac	tgtgatcatg	1020
	aaacttagta	gaggggattg	tgtgtatttt	atacaaat	atacaaatgt	cttacattga	1080
	taaaattctt	aaagagcaaa	actgcatttt	atctctgcat	ccacattcca	atcatattag	1140
	aactaagata	tttatctatg	aagatataaa	tggtgcagag	agactttcat	ctgtggattg	1200
50	cgttgtttct	taggggtcct	agcactgatg	cctgcacaag	catgtgatat	gtgaaataaa	1260
	atggattctt	ctatagctaa	atgagttccc	tctggggaga	gttctgggtac	tgcaatcaca	1320
	atgccagatg	gtgtttatgg	gctattttgtg	taagtaagtg	gtaagatgct	atgaagtaag	1380
	tgtgtttgtt	ttcatcttat	ggaaactctt	gatgcattgt	cttttgtatg	gaataaattt	1440
	tggtgcaata	tgatgtcatt	caacttttgc	ttgaattgaa	ttttggttgt	atttatatgt	1500
55	attataacctg	tcacgcttct	agttgcttca	accattttat	aaccattttt	gtacatattt	1560
	tacttgaaaa	tattttaaat	ggaaatttaa	ataaacattt	gatagtttac	ataataaaaa	1620
	aaaaaa						
	<210>	25					
	<211>	1420					
60	<212>	DNA					
	<213>	Human					
	<400>	25					
65	gttcagcatt	gtttctgctt	ctgaaatctg	tatagtacac	tggtttgtaa	tcattatgtc	60





	ggtgaactca	gtgcattggg	ccaatgggtc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acgggtttggc	tgctgggtggg	ctttcccttc	actgtcattg	gaggcatctt	120
	tggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
5	gattccaccc	cagccctggg	acaagtctac	tgatcatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tgagagctgta	ctacatcttt	gccacagtat	ggggctcgga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgcactca	cctacttcca	gttgtctggg	gaggattacc	gctgggtggg	420
	gcgactctgtg	ctgagtgttg	gctccacccg	cctcttcac	ttcctctact	cagttttcta	480
10	ttatgcccg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttcctcat	gctgggcacc	atctcctttt	tttcttccct	600
	aaagtccatc	cggatatatct	atgttaacct	caagatggac	tgagtctctg	atggcagaac	660
	tattgctggt	ctctcccttt	cttcatgccc	tggtgaactc	tcctaccagc	ttctcttctg	720
	attgactgaa	ttgtgtgatg	gcattgttgc	cttccctttt	tccttttggg	cattccttcc	780
15	ccagagaggg	cctggaaatt	ataaatctct	atcacataag	gattatata	ttgaactttt	840
	taagttgcct	ttagttttgg	tcctgatttt	tctttttaca	attacaaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
	<210>	29					
20	<211>	1775					
	<212>	DNA					
	<213>	Human					
	<400>	29					
25	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaatgt	ccgaagggat	tttggccaac	60
	accagaaaaac	gccaatgtcc	taggaattcc	ctccaaaaat	gcttcccaaa	aaattactca	120
	ttgacaatttc	aaattgcaact	tggttgccg	cagcccgggc	ggccttcagt	cgtgtgggg	180
	cgcccgcggtg	gcctttctct	cgtaggactc	cccaaactcg	ttcactctgc	gtttatccac	240
30	aggataaagc	caccgctggg	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccgggtga	gacgtgggca	tggtgatgat	gaaggcaaa	acgtcatcaa	tgaaggtggt	360
	gaaagccttg	taggtgaagg	ccttccaggg	cagatgtgcc	actgacttca	actttagatt	420
	cacaaaagagc	tggggcagca	tgaagaggaa	accaaaaggca	tagaccccg	tgacgaagct	480
	gttgattaac	caggagtacc	agctcttata	tttgatattc	aggagtgaat	agacagcacc	540
35	cccagacacag	agagggtaca	gcaggatga	caagtacttc	atggcctgag	tatcgtactc	600
	ctcgggttttc	ctctcagatt	cgtgtgaagt	gccaaactga	aattcgggca	tcaggcctct	660
	ccaaaaataa	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggctccaac	720
	accgcgcggg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
	cacgggtgctg	aagcagcgcc	agagcactgc	cttgggtggac	atgccgatca	tgctcttctt	840
40	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaaag	aaggtcagcg	ccaggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaaccgaa	ctgctgcagg	gagtacacgg	cgtcctgcat	1020
	gtggatccag	aagcgcagcc	gccccagtga	gaccttgctg	taggacacgg	tgaggggcag	1080
	ctcgggtggg	gagcggttta	tgaccatcag	gtccttcacg	cggttgctga	gctggctgat	1140
45	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcggga	ggcaggagg	accgctcaaa	gacaaagtgt	tcgcatca	cgttcagcgc	1260
	cagccgcggg	cgccagtggg	acactggctc	atccagggca	ctcgtcggt	tcttctccgc	1320
	ctcgtatctgc	tgtgtatcag	actccccggg	gagcagggtg	atttcttctg	gcttggggac	1380
	catgtagggtg	gtcagaggac	tgaccagggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
50	cccagcgtga	tggaggaaag	tgtaggcata	cagcgtccca	ttgtttctcg	ttttcttttg	1500
	tacagaaaca	ttactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccagggtcg	atgttgttct	cagcaccag	gtgggacctc	gtcgtgggtg	acacgtcag	1620
	ctgcagcttg	ggccgcgcg	ccaggtaggg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
55	gcgggtgtag	acgatgccgt	acatgaccca	gcagggtgtgc	accacgtaga	ccacgaacac	1740
	gcccaccacc	aagctggtga	aggagctgcg	gcccc			
	<210>	30					
	<211>	1546					
	<212>	DNA					
60	<213>	Human					
	<400>	30					
65	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgaacca	ttcttttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tgttggttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tgttgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagtcc	aattaaaaca	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcacac	cttctaaaaac	tgggtacatta	600
	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	gggtgaaaaa	atgcaagcac	ttcagcaacc	agccggctct	attccagtat	tattttgccc	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	ttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgaact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctagggaaa	ggaattttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
20	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatataa	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcacaaa	aggtgtgctg	60
35	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatttc	tgtttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactattttc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccac	ggtcttgtaa	aaagggaagt	tgaatacaga	gccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatcatcaa	cacagacacg	atttggaact	cctgacaggt	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgtcac	caccgtcccc				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	ctgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttgcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgtttctgg	ttttttcctt	ctttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttacttta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaaggcca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtccctt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
65	tggagttgtg	cacaaaaaatt	aggtcatgcc	ttcagtgtct	tgttctttaa	acctaccctt	720
	tgacaatcag	gtgctaataa	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgattttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
5	cagtattatg	tttacaatcc	attggatgag	tgacagatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtcttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactcg	tgcaaaactct	gatgatacct	gcttatgtgg	1200
	attcttttcc	acatagcttt	cattttttaag	tataaaagact	tagaaaaacta	gaataatgct	1260
	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
10	atttaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	ccttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	aggggtattat	atatataaat	1560
15	acatatatac	cctttgtaacc	tttatactgt	aaataaaaaa	gttgctttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggagggg	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgacagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgac	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	taattattga	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	aggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggatcacac	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtagcgatt	540
	ccaggaaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcattg	tttggagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgtagcactc	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgtactt	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ccttgggtacc	tacctctgca	catactgggt	atggcatggg	aagtcctgat	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	ctgggcgttt	gaaggaagga	gatacaatca	ttgttctctg	agtagaaggg	1140
	ccatttgtaa	ctcagattcg	aggcctcctg	ttacctcctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattccttga	1260
45	aaagacctgg	agaaaacatt	ggctgggtta	cccctccttg	tggtttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgccagggca	ctcacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtagatttt	taattctcga	gatccgatag	tgatgggggt	gacggtggaa	1800
	gcaggctcagg	tgaaacaggg	gacacccatg	tggtgtccaa	gcaaaaattt	tgtagacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttggg	taaaaataga	acctatccct	gggtgagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtcatttga	tgactcctaa	2040
	gactgggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcattctaatt	ttttcacatg	gagcaggaac	tggaagtaaat	gcaatactgt	2160
60	ggttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaagggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgttttaaag	tttgccttct	2400
	cccaaatgtg	gattttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
	gtacttcgagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	ttttgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cctttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

5	agctgctttg	tgtgaaacca	tggtgtaaaa	gcacagctgg	ctgcttttta	ctgcttgtgt	2700
	agtcacgagt	ccattgtaat	catcacaatt	ctaaaccaa	ctaccaataa	agaaaacaga	2760
	catccaccag	taagcaagct	ctgttaggct	tccatgggta	gtggtagctt	ctctcccaca	2820
	agttgtcctc	ctaggacaag	gaattatctt	aacaaactaa	actatccatc	acactacctt	2880
	ggtagtccag	cacctgggta	acagtaggag	attttataca	ttaatctgat	ctgtttaatc	2940
	tgatcggttt	agtagagatt	ttatacat				
	<210>	34					
	<211>	6011					
10	<212>	DNA					
	<213>	Human					
	<400>	34					
15							
20	acggggcgcc	ggacgacccg	cacatcttat	cctccacgcc	ccactcgac	tcggagcggg	60
	accgcccggg	actccccctc	gggcccggca	ctcgaggagt	gaggagagag	gccgccggcc	120
	cggtctgagc	cgagcgcagc	accccccgcg	ccccgcgcca	gaagtttggt	tgaaccgggc	180
	tgccgggaga	aacttttttc	ttttttcccc	ctctcccggg	agagtctctg	gaggaggagg	240
	ggaactcccc	cggcccaagg	ctcgtgggct	cggggtcgcg	cggccgcaga	agggcgggg	300
25	tccgcccgcg	aggggagggc	ccccgggga	cccgagaggg	gggtgaggac	cgcgggctgc	360
	tggtgcggcg	gcggcagcgt	gtgcccccg	caggggaggg	gccgcccgc	tcccgcccg	420
	gctgcgagga	ggaggcggcg	gcggcgcagg	aggatgtact	tggtggcggg	ggacaggggg	480
	ttggccggct	gcgggcacct	cctgggtctc	ctgctggggc	tgctgctgct	gccggcgcg	540
	tccggcacc	gggcgctggt	ctgcctgccc	tgtgacgagt	ccaagtgcga	ggagcccagg	600
30	aaccgcccgg	ggagcatcgt	gcagggcgct	tgcggtgct	gctacacgtg	cgccagccag	660
	gggaacgaga	gctcgggcg	caccttcggg	atttacggaa	cctgcgaccg	ggggctgcgt	720
	tgtgtcatcc	gcccccgct	caatggcgac	tccctcaccg	agtacgaagc	gggcgtttgc	780
	gaagatgaga	actggactga	tgaccaactg	cttggtttta	aacctgcga	tgaaacctt	840
	attgctggct	gcaatataat	caatgggaaa	tgtgaatgta	acaccattcg	aacctgcagc	900
35	aatccctttg	agtttccaag	tcaggataatg	tgcttttcag	ctttaagag	aattgaagaa	960
	gagaagccag	attgtccaa	ggcccgtgt	gaagtccagt	tctctccacg	ttgtcctgaa	1020
	gattctgttc	tgatcgaggg	ttatgtcct	cctggggagt	gctgtccctt	accagccgc	1080
	tgctgtgca	acccgcgagg	ctgtctgcgc	aaagtctgcc	agccgggaaa	cctgaacata	1140
	ctagtgtcaa	aagcctcagg	gaagccggga	gagtgtgtg	acctctatga	gtgcaaacca	1200
40	gttttcggcg	tgactgcag	gactgtggaa	tgccctactg	ttcagcagac	cgctgtctcc	1260
	ccggacagct	atgaaactca	agtcagacta	actgcagatg	gttgctgtac	tttgccaaca	1320
	agatgcgagt	gtctctctgg	cttatgtggt	ttccccgtgt	gtgaggtggg	atccactccc	1380
	cgcatagtct	ctcgtggcga	tgggacacct	ggaaagtgt	gtgatgtctt	tgaatgtgtt	1440
	aatgatacaa	agccagcctg	cgtatttaac	aatgtggaa	attatgatgg	agacatgttt	1500
45	cgaatggaca	actgtcggtt	ctgtcgatgc	caaggggcg	ttgccatctg	cttcaccgcc	1560
	cagtgtgtgtg	agataaactg	cgagaggtac	tacgtgccc	aaggagagtg	ctgcccagtg	1620
	tgtgaagatc	cagtgtatcc	ttttaataat	cccgtgtggt	gctatgccaa	tggcctgatc	1680
	cttggcccacg	gagaccgggtg	gcgggaagac	gactgcacat	tctgccagtg	cgtcaacggt	1740
	gaacgccact	gcgttgcgac	cgtctgcgga	cagacctgca	caaaccctgt	gaaagtgcct	1800
50	ggggagtgtt	gccctgtgtg	cgaagaacca	accatcatca	cagttgatcc	acctgcatgt	1860
	ggggagtatt	caaactgcac	tctgacacgg	aaggactgca	ttaatggttt	caaacgcgat	1920
	cacaatggtt	gtcggacctg	tcagtgcata	aacacccagg	aactatgttc	agaacgtaaa	1980
	caaggtgca	ccttgaactg	tcccttcggt	ttccttactg	atgcccaaaa	ctgtgagatc	2040
	tgtgagtggc	gcccagggcc	caagaagtgc	agaccataa	tctgtgacaa	gtattgtcca	2100
55	cttggaattgc	tgaagaataa	gcacggctgt	gacatctgtc	gctgtaagaa	atgtccagag	2160
	ctctcatgca	gtaagatctg	ccccttgggt	ttccagcagg	acagtcacgg	ctgtcttata	2220
	tgcaagtgca	gagaggcctc	tgtctcagct	gggccaccca	tcctgtcggg	cacttgtctc	2280
	accgtggatg	gtcatcatca	taaaaatgag	gagagctggc	acgatgggtg	ccgggaatgc	2340
	tactgtctca	atggacggga	aatgtgtgcc	ctgatcacct	gcccggtgcc	tgctgtggc	2400
60	aacccaccca	ttcacctggg	acagtgtgct	ccatcatgtg	cagatgactt	tgtggtgcag	2460
	aagccagagc	tcagtactcc	ctccatttgc	cacgcccctg	gaggagaata	ctttgtggaa	2520
	ggagaacagt	ggaacattga	ctcctgtact	cagtgcacct	gccacagcgg	acgggtgctg	2580
	tgtgagacag	aggtgtgccc	accgctgctc	tgccagaacc	cctcacgcac	ccaggattcc	2640
	tgctgcccac	agtgtacaga	tcaacctttt	cggccttcct	tgtcccgcga	taacagcgta	2700
65	cctaattact	gcaaaaatga	tgaaggggat	atattcctgg	cagctgagtc	ctggaagcct	2760
	cacgttttga	cagctgcat	ctgcattgat	agcgtaatta	gctgtttctc	tgagtctctg	2820
	ccttctgtat	ccgtgtgaaag	acctgtcttg	agaaaaggcc	agtgtgttcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	ggtggtgtgc	cacttcagtg	ggaaggccta	tgccgacgag	2940

	gagcgggtggg	accttgacag	ctgcacccac	tgtactgccc	tgcagggcca	gaccctctgc	3000
	tgcacgtca	gctgcccc	tctgcccgt	gttgagccca	tcaacgtgga	aggaagtgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aacctcgag	gagagggtga	cctggagggt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagt	aagattcttc	actggactcc	attgcctcag	ttgtgggtcc	cataattata	3300
	tgcctctcta	ttataatagc	attcctattc	atcaatcaga	agaaacagt	gataccactg	3360
	ctttgctggt	atcgaaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccagggt	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggctcttac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgagggttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
15	atgtgcagaa	caagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
	ccaaagtitt	taaagtgtgt	aagatatatt	tgcctgtaag	atagctgtag	agatatttgg	3840
	gggtggggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggg	aacataaaag	cagttcagtg	gccagagggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctggttgctg	caaagctcag	gcctgaatga	4020
20	gcaggaaaaca	aaaaaggcct	tgcgaccag	ctgcataaac	caccttagaa	ctaccagag	4080
	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagtgt	ctttctata	4140
	cagtcacaac	tgcagtaggc	agtgaggaag	ccagagaaat	gcgtagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttat	tctccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
25	atgtgagcac	tggaactttt	tttttttaca	acgtgacagg	aagaggagg	agagggtgac	4380
	gaacaccagg	catttccagg	ggctatat	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaaag	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgtttgg	ggattctttt	tccttattat	atactgattc	tacaaaaatg	aaactacttc	4560
	attttaattg	tattattatt	aagcaccttt	gttgaagctc	aaaaaaaaat	atgcctcttt	4620
30	aaacttttag	aattatagga	gtattttgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttctct	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
35	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attcctttat	taaaaatctc	ctcatttggg	tttgctttca	gttggttttc	aatttgcctc	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatcact	aatcagctcc	tggatttttt	5100
	tttttttttt	tcaaacatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttgggt	tagtatgcct	caaataatac	tgactgtata	ctatagtggg	aacttttcaa	5220
40	acagccctta	gcacttttat	actaattaac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
	tgcttggtgt	gaaagacaca	gataccaggt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaataactgg	acagagggtg	ctgaacttta	5400
	aaaaaaaatta	atttattatt	ataattgacct	aatttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaaggaa	5520
45	aaaaagattt	attatcaagg	ggcaatat	ttatcttttc	caaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	ttgttttttt	5700
	caatcatggc	catattatga	aaataactac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttactttggg	5820
	tcctgtgttg	ctcttgtaaa	agaaaaatat	aatttctctg	agaataaaa	agatatatgg	5880
50	cacttgaggt	gcacataggt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpqsiqvqvc	60
65	gccytcasgg	nescgggtfgi	ygctcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
	gfkpcnenli	ecntirtcsn	pfefpsqdmc	lsalkrieec	kpdcskarce		180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

	ccdlyeckpv	fgvdertvec	ptvqqgtacpp	dsyetqvrll	adgcctlptr	ceclsglclgf	300
	pvcevgstpr	ivsrgdgtpg	kccdvfecvn	dtkpacvfnn	veyydgdmfr	mdncrfrcrq	360
	ggvaicftaq	cgeinceryy	vpegeccpvc	edpvypfnnp	agcyanglil	ahgdrwredd	420
5	ctfcqcvnge	rhcvatvcgq	tctnpvkvpq	eccpvceep	iitvdppacg	elsnctltrk	480
	dcingfkrdh	ngcrtcqcin	tqelcserkq	gctlncpfgf	ltdaqnceic	ecrprpkcr	540
	piicdkycpl	gllknkhgdc	icrckkcpel	scskicplgf	qgdshgcllc	kcreasasag	600
	ppilsgtclt	vdghhkhnee	shwdgcrecy	clngremcal	itcpvpacgn	ptihpgqccp	660
	scaddfvvqk	pelstpsich	apggeyfvge	etwnidsctq	ctchsgrvlc	etevcppllc	720
	qnpstrtdsc	cpqctdqpfr	pslsrnnsvp	nyckndegdi	flaaeswkp	vctscicids	780
10	viscfesescp	svsccrpvlr	kgqccpycik	dtipkkvch	fsgkayadee	rwlddscthc	840
	yclqggtlcs	tvscpplpcv	epinvegsc	pmcpemyvpe	ptnipiekt	hrgevdlevp	900
	lwptpsendi	vhlprdmghl	qvdyrdrnlh	psedssldsi	asvvvpiiic	lsiiiaflfi	960
	nqkkqwipll	cwyrtptkps	slnnqlvsvd	ckkgtrvqv	ssqrmrlrae	pdarfsgfys	1020
15	mqqkqnhlqad	nfyqtv					
	<210>	35					
	<211>	716					
	<212>	DNA					
20	<213>	Human					
	<400>	35					
25	gcagtagctg	gagtgctctg	cagggggaaa	gcgaaccggg	cctgaagtc	cggggcagtc	60
	acccggggct	cctggggccg	tctgccgggc	tggggctgag	cagcgatcct	gctttgtccc	120
	agaagtccag	agggatcagc	cccagaacac	accctcctcc	ccgggacgcc	gcagctttct	180
	ggaggctgag	gaaggcatga	agagtgggct	ccacctgctg	gccgactgag	aaaagaattt	240
30	ccagaactcg	gtcctatttt	acagattgag	aaactatgg	tcaagaagag	aggacggggc	300
	ttgagggaat	ctcctgattc	tccttatatg	acctcaaact	gaccatacta	aacagtgtag	360
	aaggtctttt	taaggctcta	aatgtcagg	tctcccatcc	cctgatgcct	gacttgtaca	420
	gtcagtgtgg	agtagacggt	ttcctccacc	cagggttgac	tcagggggat	gatctgggtc	480
	ccattctggt	cttaagacc	caaacaagg	ttttttcagc	tccaggatct	ggagcctcta	540
	tctggttagt	gtcgtaacct	ctgtgtgcct	cccgttacct	catctgtcca	gtgagctcag	600
35	cccccatcca	cctaacagg	tgccacagg	gattactgag	ggtaagacc	ttagaactgg	660
	gtctagcacc	cgataagagc	tcaataaatg	ttgttccttt	ccacatcaaa	aaaaaa	
	<210>	36					
	<211>	395					
40	<212>	DNA					
	<213>	Human					
	<400>	36					
45	ccaatacttc	attcttcatt	ggtggagaag	attgtagact	tctaagcatt	ttccaaataa	60
	aaaagctatg	atttgatttc	caacttttaa	acattgcatg	tcctttgcc	tttactacat	120
	tctccaaaaa	aaccttgaaa	tgaagaaggc	cacccttaaa	atacttcaga	ggctgaaaat	180
	atgattatta	cattggaatc	ctttagccta	tgtgatattt	ctttaacttt	gcactttcac	240
	gccagtaaaa	accaaagtc	gggtaaccaa	tgtcatttta	caaatgtta	aaacccta	300
50	tgagttcct	tttttaaat	attttaaaga	ttacttaaca	acattagaca	gtgcaaaaaa	360
	agaagcaagg	aaagcattct	taattctacc	atcct			
	<210>	37					
	<211>	134					
55	<212>	DNA					
	<213>	Human					
	<400>	37					
60	ccctcgagcg	gccgcccggg	caggtacttt	taccaccgaa	ttgttcactt	gactttaaga	60
	aaccataaaa	gctgcctggc	tttcagcaac	aggcctatca	acaccatgg	gagtcctcat	120
	aaggacaccc	gtgt					
	<210>	38					
65	<211>	644					
	<212>	DNA					

&lt;213&gt; Human

&lt;400&gt; 38

```

5  aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
   cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
   gggaaagagt ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
   ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
   gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10  ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaaagtttt aggagaaaaga 360
   aggatgttta tgttccagag gccagtcgct cacatcagtg gcagacagat gaagaaggcg 420
   ttgcaccgag aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
   caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
15  tcaaaggctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
   gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

```

&lt;210&gt; 39

&lt;211&gt; 657

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 39

```

25  ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
   gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
30  agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
   tggctccttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
35  atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

```

&lt;210&gt; 40

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Human

40

&lt;400&gt; 40

```

45  acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
   ctggttagtt tttgtaggct cattatgggt agggctggtt agatgtatat aagaacctac 120
   ctatcatgct gtatgtatca ctcatccat tttcatgttc catgcatact cgggcatcat 180
   gctaatatgt atccttttaa gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attcccaaaa tttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
50  acttccttca cagtgcctg tctaccacta caaggactgt gcatctaagt aataattttt 420
   taagattcac tatatgtgat agtatgatat gcattttatt aaaatgcatt agactctctt 480
   ccacccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
   tgaagagatc agtagtaaga attccatttt cctcatcag tgaagacacc acaaattgaa 660
55  actcagaact atatttctaa gcctgcattt tcatgatgac ataattttct tagtaattat 720
   aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaattttat gagaagggtat tcttcatttt aattgctttt gggattactc cacatctttg 840
   tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
   attggattga catatgggtt gccagcctat gggtttacag gcattgcccc aacatttctt 960
60  tgagatctat atttataagc agccatggaa ttccctattat gggatgttgg caatcttaca 1020
   ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctctc 1080
   gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
   tggaaataag aaagggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
65  ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
   tgaaaaaa

```

	<210> 41					
	<211> 987					
	<212> DNA					
	<213> Human					
5	<400> 41					
	aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60					
	tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120					
10	taacccccgg ctatcagtcg ggatgggttg caccctcctt gctgtaggat ggaagcagcc 180					
	atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240					
	tgtttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300					
	tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcatt 360					
	aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420					
15	ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480					
	gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540					
	tgcataagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600					
	gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660					
20	cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720					
	tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatccaaa 780					
	aatagtctac ggccatacca ccctgaacgt gcctaattct gtaagctaag cagggtcagg 840					
	cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900					
	actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960					
25	tgaagtagcg atttgggtgtg aaaaaaa					
	<210> 42					
	<211> 956					
	<212> DNA					
	<213> Human					
30	<400> 42					
	cgagcgggtg ggcggacgcg tgggtgcagg agcaggggcg ctgccgactg ccccaaccaa 60					
	ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120					
35	ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180					
	tcaggggatg tttacctggt gtcggggaag ggaggggaag gggccgggga gggggcacgg 240					
	caggcgtgtg gcagccacac gcaggcggcc agggcgggca gggaccctaa gcaggatgac 300					
	cacgcacctc cacgccaact cctccccga atgcatttgg aaccctaatg taaactgagc 360					
40	tcgcagcccc cgcgcccccc ctccgcctcc catcccgctt agcgtctctg acagatggac 420					
	gcaggccctg tccagcccc agtgcgctcg ttccggctcc cacagactgc cccagccaac 480					
	gagattgtct gaaaccaagt caggccaggt gggcggacaa aaggggccagg tgcggccttg 540					
	ggggaacgga tgcctcgagg actggactgt tttttcaca catcgttgcc gcagcgggtg 600					
	gaaggaaagg cagatgtaaa tgatgtgttg gtttacagg tatatttttg ataccttcaa 660					
	tgaattaatt cagatgtttt acgcaaggaa ggacttacc agtattactg ctgctgtgct 720					
45	tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780					
	tcgcaggacc aaggggggcg ggaactgctg ctacagcccc gctgtgtcct ccctccccctc 840					
	ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggg 900					
	ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa					
50	<210> 43					
	<211> 536					
	<212> DNA					
	<213> Human					
55	<400> 43					
	aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60					
	cccttagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120					
60	agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180					
	ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240					
	tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300					
	cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360					
	attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420					
	ctggaaaaag tgggttatgc caccttttaa accctttctg gtaaataatta tggtagctaa 480					
65	agggtaggtt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt					



<210> 44  
 <211> 1630  
 <212> DNA  
 <213> Human

5

<400> 44

```

ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctcccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctatttttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atcccctctg gaggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggcccatt 360
catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
gactttacct gatlgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cggggggtggg tgggtggtggg gggctagtgt ggtttgaatt taggggcccga 660
tgagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtcccctt 720
ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggg 840
gcccagtgac ctggggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gttagagcctt cttagaggttc agaataattag cttcaggatc agctgggggt 1020
atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagt 1140
aggctggagg gagttaaggt cagtatggaa gataggggtg ggacagggtg ctttggaatg 1200
aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgtgct gtgaagatga 1260
gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatocattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgccctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
cctcttgccct cttgtagaat gcagctctgg ccctcaataa atgcttctctg cattcatctg 1620
caaaaaaaaaa

```

<210> 45  
 <211> 169  
 <212> DNA  
 <213> Human

40

<400> 45

```

tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggt ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttgaaga cttagtgtga

```

<210> 46  
 <211> 769  
 <212> DNA  
 <213> Human

50

<400> 46

```

tgcaggatcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcggtgga 60
atgtgtcgtc ttactttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
aagggtgtact aggcaatctt agagatcttg caacttattt tatatataag gcatctgtga 300
ccaagatagc ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt gtctcagaga tcttgactgg ctgtggccct 420
ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
ttgatatacg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

```

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47  
 <211> 2529  
 <212> DNA  
 <213> Human

<400> 47

10 ttttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60  
 gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120  
 tcaggacctg gtcctagtcc acaaggggtg caggaggagg gtggaggcta agaacacaga 180  
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240  
 ggatggtggg aagggggctc cctggtgggg ccgagccagg agtcccaagt cagctctcct 300  
 15 gccttaactta gctcctggca gaggtgagt ggggacctac gaggttcaaa atcaaatggc 360  
 atttggccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420  
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480  
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcc ctctccctcc 540  
 actagtggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600  
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagt 660  
 ggtgccccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttctctac 720  
 caagtggatt cggcatatga accacctact caatacttta tttttgtot gtttaaacac 780  
 tgaactctgg tgttgacagg taaaaaggag aagagatggg gactgtgaag aggggagggc 840  
 ttccctcctc ttccctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900  
 25 gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtg 960  
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020  
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080  
 aggtgaacag tctacactgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140  
 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200  
 30 gaggggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260  
 acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320  
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380  
 ccctttcctt gctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440  
 gcagttgggc tgacctgaca aagccccag tttcctgtgg caggttctgg gagaggatgc 1500  
 35 attcaagctt ctgcagccta ggggacaggg ctgctgttcc agttattact gcctcggagc 1560  
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620  
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680  
 agggagaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740  
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800  
 40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860  
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920  
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980  
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040  
 45 tgaattttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100  
 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtccaggacct 2160  
 gcagaactgg ctgaacaag atttcatgggt gtcaacctag agagatgact caatgccaa 2220  
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggct 2280  
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccactga 2340  
 50 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400  
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460  
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520  
 ggggtgtcc

<210> 48  
 <211> 1553  
 <212> DNA  
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60  
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120  
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180  
 ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240  
 65 ggggccccta gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300  
 tgaaggacag ttagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaagtga cacgggggat tgaggcta atcacctgaac 420  
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttctttt ttttcctcga 480  
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggctctcg gctcactgca 540  
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600  
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660  
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720  
 aagtgtctgg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780  
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840  
 10 agacaggagg gtggtggcag caacactgca gctgctctg gatgtgctg ggggtgctctc 900  
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960  
 acttcagtgg tgcacctgga tgggtgaagc cagcctttgg ggcaggaaac cagctcagag 1020  
 aggtacacca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaag 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 15 ggatgagctt cactcaacgt ggagatgggt gtggactggg cctgaaaag cgggcttgc 1200  
 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320  
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaatagcc 1380  
 tcagatcgat gtatttctct cctggtcttc cggagccct cttgtcaccg ctgctgcctt 1440  
 gcagggaggc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500  
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

&lt;210&gt; 49

&lt;211&gt; 921

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 49

30 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagtggga 60  
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataacct 120  
 gtctcagaaa acaaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 gctctgcaga acacttggtc actcctaccc cagatcagtg gacctgggaa tgagggttgg 240  
 tcccgggagg cttttctcca agctgttgcc accagaccog ccatgggaac cctggccaca 300  
 35 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420  
 tgctgtcctg tgtgtgtgcg tgcccctccc ctgcagccgt cgggtggtatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc caggtgagac tgcccagaga cagcagagct 540  
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctgcctgt atctcatgac 600  
 40 caggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660  
 gtcccgtgta cctgcccccg tggcgtctca cgggtgatgc tgctcctgac attggtgttc 720  
 actgtagcaa actacattct ggtggtgaat ttctatgtac atgtgtggca tgtggaaaat 780  
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840  
 tactttgacc tcttgccctac aacccttccc ttgggtccga ggctggtagc tttgttccat 900  
 45 tcagatgggt gggggcgggg g

&lt;210&gt; 50

&lt;211&gt; 338

&lt;212&gt; DNA

50 &lt;213&gt; Human

&lt;400&gt; 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60  
 tcccttcocag atattacccc atttctctac ttccatttgt agccaaactt tccaaaaatt 120  
 catgtttctgt cttcatttcc tcatgttcaa cccacctgtg cttagctacc acccctcagt 180  
 aacgacctag cctgggtaga aacaaatgtc agcatgatac cataactaat gatccttcgt 240  
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgcatac 300  
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 &lt;210&gt; 51

&lt;211&gt; 1191

&lt;212&gt; DNA

&lt;213&gt; Human

65 &lt;400&gt; 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60  
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120  
 cctggaaaat aatgaattgg gtaaggaaca gtttaataaga aaatgtgcct tgctaactgt 180  
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240  
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300  
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360  
 aatttctcta tttctccact ggtgcaaaga gcggtttct ccctgcttct cttctgtcac 420  
 ccccgtcct ctccccagc aggtcctctg atttatggta gctttggact tgcttccccg 480  
 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540  
 10 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600  
 aagacaaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660  
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720  
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780  
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840  
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900  
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960  
 ctagggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020  
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080  
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtataa gtttaagatg 1140  
 20 atgggcaaaa gtccagtgtg ttcagtaaag tgctaatacac aagttggagg t

&lt;210&gt; 52

&lt;211&gt; 1200

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 52

30 aacagggact ctcaacttat caaccccagg ctggagtccg gtgcgcccac cctggctccc 60  
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120  
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180  
 cgcttctgt ccaggccggc atcatatact ttaaatacatg cccagatgac ttaataacct 240  
 aatacaatat acagggttg tttaaaaata attgcttttt tattattttt gcatttttgc 300  
 35 accaacctta atgctatgta aatagttggt atactgttgc ttaacaacag tatgacaatt 360  
 ttgggttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420  
 ttctcagtggt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480  
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540  
 atatgtagt aaagtttatgg tacagtggaa agagttagttg aaaacataaa catttggaac 600  
 40 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggttc 660  
 tgctactaat tagctataat ctttgcacaa attacatcac ctttgagtct cagttgcctc 720  
 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780  
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840  
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900  
 45 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctattttatt 960  
 agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020  
 gctgcctcaa attcatgggc tcaagtgate ctctgcctc tgccctcaga gtactgcga 1080  
 ctatgggcat gtgccaccac gcctgggctaa catttgattt gacctattta tttattgtga 1140  
 tttatatctt tttttttttt tctttttttt ttttttacaa aatcagaaat acttattttg 1200

50 &lt;210&gt; 53

&lt;211&gt; 989

&lt;212&gt; DNA

&lt;213&gt; Human

55 &lt;400&gt; 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga cttttatttt 60  
 tatgcctttc ttcttatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120  
 gattcaatta gtccttgggc tggctcagctg tgcaggagtc caggggagcct ctacaaatgc 180  
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttcctcca 240  
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaa 300  
 cgactgtgat agagggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360  
 gtttgccttg tgcccaggct gagtgcattg cgtgatctca ctactgcaa ttccacctcc 420  
 aggttcaagg atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480  
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540  
 cccaacctca gtgatctgcc acctcagcct cctaagtggt ggattacagg atgagccacc 600

5	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgtc	ctgtcgccca	gcgggagtgc	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccacccg				
10	<210> 54						
	<211> 250						
	<212> DNA						
	<213> Human						
15	<400> 54						
	catttcccca	ttggtcctga	tgttgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtggtagg	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
20	aaagggcatt	cttttaggaac	tgcatctggt	aaccacaccc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210> 55						
	<211> 2270						
25	<212> DNA						
	<213> Human						
	<400> 55						
30	gcgcccccca	gcagcgcccc	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggcccgcgcg	ccgcccagcc	ctgcctcccc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgacggcct	gtccgctgca	caccagcttg	ttggcgctct	cgtcgcccg	180
	ctcgccccg	gctaactctg	cgcgccacaa	tgagctcccc	catcgccagg	gcgctcgct	240
	tagtcgtcac	ccttctccac	ttgaccaggc	ttggcgctctc	cacctgcccc	gctgcctgcc	300
35	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtccg	gctggctccg	gacggctgcg	360
	gctgctgtaa	ggtctgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataaactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gccccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tcccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtcgg	660
	tcaaagttac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttggca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggctcc	840
	ctgttttttg	aatggagcct	cgcatcctat	acaacccttt	acaaggccag	aaatgtattg	900
45	ttcaaaacac	ttcatgttcc	cagtgtctca	agacctgtgg	aactgggtatc	tccacacgag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatcccccca	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttctctg	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
50	tgaagtgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
	agtcctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcggtt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caagggagaa	gagtgtcaga	atcagaatca	tggagaaaat	gggcgggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
55	ggtatttcga	aactgccaag	ggtgctgggt	cggtatggaca	ctaatgcagc	cacgattgga	1560
	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcatattttc	tctaggcttt	1680
	tttctttttg	gggttctaca	gtcgtaaaag	agataataag	attagtttga	cagttttaaag	1740
	cttttattcg	tccttttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
60	acaactccat	agtgtctgtg	agaggcagct	atctgcactc	taaaactgcaa	acagaaatca	1860
	ggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttg	taaatgattt	taattttata	ttcagtgaag	agattttatt	1980
	tatggaatta	accattttaat	aaagaaatat	ttaccttaata	tctgagtgtg	tgccattcgg	2040
	tatttttaga	ggtgctccaa	agtcattagg	aacaacctag	ctcagctact	caattattca	2100
65	aacagacttt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
	ttataccttc	agttagagaaa	agtcctttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

10	cttgaatgaa	gctgacacca	agaaccgcgg	gaagagcttg	ggcccaaagc	agggaaagga	60
	agcgctcgag	ttggaagga	accgctgctg	ctggccgaac	tcaagcccgg	gcgccccac	120
	cagtttgatt	ggaagtccag	ctgtgaaacc	tggagcgtcg	cctctcccc	agatggctcc	180
	tggtttgctt	ggtctcaagg	acactgcatac	gtcaaaactga	tccccgggc	gttggaggag	240
15	cagttcatcc	ctaaagggtt	tgaagcmeta	agccgaagta	gcmetaagga	gacgaaaggg	300
	cggggcagcc	caaaagagaa	gacgctggac	tgtggtcaga	ttgtctgggg	gctggccttc	360
	agcccggtgc	cttccccacc	cagcaggaag	ctctgggcac	gccaccacc	ccaagtgcc	420
	gatgtctctt	gcctggttct	tgtcatcgga	ctcaacgatg	ggcagatcaa	gatctgggag	480
20	gtgcagacag	ggctctctgt	tttgaattct	tccggccacc	aagatgtcgt	gagagatctg	540
	agcttcacac	ccagtggcag	tttgattttg	gtctccgcgt	cacgggataa	gactctcgc	600
	atctgggacc	tgaataaaca	cggtaaacag	attcaagtgt	tatcggggca	cctgcagtgg	660
	gtttactgct	gttcacatct	cccagactgc	agcatgctgt	gctctgcagc	tggagagaag	720
25	tcggtcttct	tcttggagcat	gaggctctac	acgttaattc	ggaagctaga	gggccataca	780
	agcaagtgtg	tatctttgtga	ctctctcccc	gactctgcc	tgtctgtcac	ggctctctac	840
	gataccaatg	tgatttatgtg	ggacccttac	accggcgaaa	ggctgaggtc	actccaccac	900
	accaggttg	acccgcgcat	ggatgacagt	gacgtccaca	ttagctcact	gagatctgtg	960
30	tgcttctctc	cagaaggctt	gtaccttgcc	acggtggcag	atgacagact	cctcaggatc	1020
	tgggcccgtg	aactgaaaac	tcccatgtga	ttgtctcta	tgaccaattg	gctttgtctc	1080
	acattttttc	cacatgtgtg	agtcatttgc	acagggacaa	gagatggcca	cgctccagttc	1140
	tggacagctc	ctagggtcct	gtcctcactg	aagcacttat	gccggaaaagc	ccttcgaagt	1200
35	ttcctaacaa	cttaccgaag	cctagcactg	ccaatcccca	agaaaatgaa	agagttcctc	1260
	acatacagga	ctttttaagc	aacacaacat	cttgtgtctc	ttttagtagc	ggtaaatctg	1320
	cctgtcaaaag	ggagttgctg	gaataattgg	ccaacaactc	ggctttgcac	tgaataatga	1380
	tttctttggg	attgtgaata	gaatgtagca	aaaccagatt	ccagtgatac	taaaagaatt	1440
35	tttttgtctt	taaatagata	caaatgtcta	tcaactttaa	tcaagttgta	acttatattg	1500
	agacaattt	gatacataat	aaaaaattat	gacaatgtcc	tgggaaaaaaa	aaaatgtaga	1560
	aagatgttga	aggatgggat	ggatgaggag	cgtggtgacg	ggggcctgca	gcgggttggg	1620
	gacctgtgc	tgcgtt					

40      <211> 400  
         <212> DNA  
         <213> Human

45	ccatgtgtgt	atgagagaga	gagagatttg	gagggagagg	gagctcacta	gcgcatatgt	60
	gcctccaggg	ggctgcagat	gtgtctgagg	gtgagcctgg	tgaaagagaa	gacaaaagaa	120
	tggaatgagc	taaagcagcc	gctctggggtg	ggagcccgag	cccatttcta	tgcagcagcg	180
	ggcaggaggcc	cagcaaggga	gcctccattc	caggactct	ggagggagct	gagaccatcc	240
	atgcccgcag	agccctccct	cacactccat	cctgtccagc	cctaatttgc	caggtgggga	300
50	aactgaggct	gggaagtca	atagcaagtg	actggcgag	ctgggactgg	aacccaacca	360
	gcctcctaga	ccacggttct	tcccatcaat	ggaatgctag	agactccagc	caggtgggta	420
	ccgagctcga	attcgtaac	atggtcatag	ctgttctctg			

55

<210>	38
<211>	1049
<212>	DNA
<213>	Human

60	atctgatcaa	gaataacctgc	cctggtcact	ctgcggatgt	ttctgtccac	ttgttcacat	60
	tgaggaccaa	gatatccttt	tttacagagg	cacttggttcg	gtctaacaca	gacacctcca	120
	tgacgacatg	ctggctcaca	ttttgcagtt	ctgcagaagt	ccccctcca	gcctggacta	180
	cagcagcact	ttcccgtggg	ggtgcagtag	ccgttttcgac	agagcctgga	gcactctgaa	240
65	gtcagtgctc	gtgcaggttg	taccgtggct	ctgcattcct	caggcattaa	aggtcttttg	300
	ggatctacaa	ttttgtagtg	ttttccattg	tgagctctggg	ctatactttt	actcgttgat	360

5   aaaatgtaaa cttcacctag ttcattcttct ccaaatecca agatgtgacc ggaaaagtag 420  
      cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480  
      ggacttttgct ggagaggttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
      aatctttctg actggcagcc ccggtatata aatccaccaa ccaaaggacc attactgaat 600  
      ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660  
      attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720  
      tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
      aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 10   ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900  
      aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
      aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020  
      acttcaagaa agactctggc tgttctcaa

15   <210> 59  
      <211> 747  
      <212> DNA  
      <213> Human

20   <400> 59

25   tttttcaaat cacatatggc ttcttttgacc ccatcaaata actttattca cacaaacgtc 60  
      ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
      cttaaatata atgtatcata ccaacccaag taaaccaagt aaaaaaata ttcataataa 180  
      gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
      atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300  
      ctcgtctgtc ccacacaaat gttaagaag tcaactgcaat gtactccccg gctctgatga 360  
      aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420  
      gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
      ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 30   ccaattcaat gccacaccta ctggttaccc tttgagggca tttctccaga cagaagcccc 600  
      ttgaagccta ggtagggcag gatcagagat acaccogtgt ttgtctcgaa gggctccaca 660  
      gcccagtacg acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
      cggaattta gtagtaatag cggccgc